OncoLens, a health tech startup focused on cancer treatment, has raised $16 million in Series A funding. The round was co-led by BIP Capital and Cross Border Impact Ventures, with additional investment from Martin Ventures and SeedToB.

The funds will be used to enhance the company’s development efforts. Led by CEO Anju Mathew, OncoLens helps optimize cancer treatment planning for national cancer institutes, academic medical centers, and community healthcare networks.

It uses AI technology to help cancer centers analyze clinical and lab data, identifying patients who may have missed important diagnostic tests or therapies. Their collaboration tools ensure that care teams can quickly coordinate the next steps for these patients.

Read also – [Funding news] NC-based mPATH Secures $3Million in Funding

The company also serves international clients, having expanded into Europe, the Middle East, and Africa in 2022. With a growing customer base, OncoLens launched the OncoLens Research Network, partnering with life sciences teams to support research and clinical trials.

For life science partners, it offers a network of community-focused centers that helps address issues like real-world evidence and diversity in clinical trials.

About OncoLens

OncoLens is an AI-driven platform that enhances teamwork, analytics, and clinical decision-making in oncology care.